The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target to cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissue and to evaluate its clinical value. Siglec-15 expression was evaluated by immunohistochemistry with 71 patients. Siglec-15 staining was observed in tumor cells of 53 (74.64%) patients, with significant association with histologic classification and angiolymphatic invasion (p<0.05). Immunohistochemistry analysis also detected Siglec-15 in tumor-associated stroma cells (macrophages/myeloid cells). There was no significant association with outcomes parameters. Siglec-15 expression in well differentiated histological GC tissues and in the tumor microenvironment are potential targets to be further investigated as a novel prognostic factor for GC.

唾液酸结合免疫球蛋白型凝集素 Siglec-15 是几种肿瘤类型癌症免疫治疗的有希望的靶点。本研究旨在研究 Siglec-15 在胃癌 (GC) 患者组织中的表达并评估其临床价值。Siglec-15 表达通过免疫组织化学对 71 名患者进行评估。在 53 名（74.64%）患者的肿瘤细胞中观察到 Siglec-15 染色，与组织学分类和血管淋巴浸润显着相关（p<0.05）。免疫组织化学分析还在肿瘤相关基质细胞（巨噬细胞/骨髓细胞）中检测到 Siglec-15。与结果参数没有显着关联。